Journal article Published 2017

Dysregulation of KRAS signaling in pancreatic cancer is not associated with KRAS mutations and outcome

Radmila Lemstrová, V. Brynychova, D.J. Hughes, V. Hlavac, P. Dvorak, J.E. Doherty, H.A. Murray, M. Crockard, M. Oliverius, J. Hlavsa, E. Honsova, J. Mazanec, Z. Kala, Martin Loveček, Roman Havlík,

Show all 20 authors

Jiří Ehrmann, Ondřej Strouhal, P. Soucek, Bohuslav Melichar, Beatrice Mohelníková Duchoňová

Oncology Letters 8(1), 1236 (2017)

View on PubMed Cite

2017 Year
29089570 PMID

Cite this publication

LEMSTROVÁ, R., V. BRYNYCHOVA, D. HUGHES, V. HLAVAC, P. DVORAK, J. DOHERTY, H. MURRAY, M. CROCKARD, M. OLIVERIUS, J. HLAVSA, E. HONSOVA, J. MAZANEC, Z. KALA, M. LOVEČEK, R. HAVLÍK, J. EHRMANN, O. STROUHAL, P. SOUCEK, B. MELICHAR, B. MOHELNÍKOVÁ DUCHOŇOVÁ: Dysregulation of KRAS signaling in pancreatic cancer is not associated with KRAS mutations and outcome. Oncology Letters. 2017, 8(1), 1236, ISSN: 1792-1074, PMID: 29089570.

Dysregulation of KRAS signaling in pancreatic cancer is not associated with KRAS mutations and outcome

Cite this publication

Details

Authors from IMTM